Dec 27, 2023, 13:21
First data showing overall survival benefit for PARPi maintenance for Ovarian Cancer – ACS Journal Cancer
ACS Journal Cancer posted on X/Twitter:
“Just published! ‘Top advances of the year: Ovarian Cancer’ by Dr. Melissa Lumish and Dr. William P. Tew of Team Ovary, Memorial Sloan Kettering Cancer Center.
Key updates:
- Mirvetuximab for PROC
- First data showing overall survival benefit for PARPi maintenance.”
Further reading.
Source: ACS Journal Cancer/X
Jul 18, 2024, 02:38